PMID- 19642044
OWN - NLM
STAT- MEDLINE
DCOM- 20100128
LR  - 20220330
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 48
IP  - 7
DP  - 2009
TI  - Interleukin-18 promoter polymorphism is associated with lung cancer: a 
      case-control study.
PG  - 971-6
LID - 10.1080/02841860902878145 [doi]
AB  - BACKGROUND: Interleukin-18 (IL-18) is a multifunctional cytokine that augments 
      IFN-gamma production and affects tumor immune response. In the present 
      case-control study, we tested whether IL-18 promoter polymorphism contributes to 
      lung cancer susceptibility in Iranian patients. MATERIAL AND METHODS: The study 
      groups were 73 patients with lung cancer, including 53 with squamous carcinoma 
      (SC) and 20 with small cell lung carcinoma (SCLC), and 97 healthy regional 
      aged-matched individuals. The frequency of IL-18 promoter single nucleotide 
      polymorphisms (SNPs) at positions -656 (G/T), -607 (C/A), and -137 (G/C) was 
      determined by polymerase chain reaction analyses. RESULTS: There were significant 
      differences in the IL-18 -607 allele and genotype distributions between the 73 
      lung cancer patients and controls. A significantly higher A allele frequency at 
      position -607, which is associated with lower IL-18 production, was observed in 
      lung cancer patients (48.6% vs. 35%; OR = 1.75; 95% CI 1.13-2.72). Also, patients 
      with the -607 CA and the AA genotypes had a 2.60-fold (95% CI 1.26-5.36) and 
      3.15-fold (95% CI 1.16-8.55) increase in risk of lung cancer. Subdivision of the 
      patients according to histological type revealed that SC was significantly 
      associated with IL-18 -607 SNPs. Although the percentages of -607 alleles and 
      genotypes in SCLC patients were similar to the results in SC patients, the 
      differences compared to control individuals did not reach statistical 
      significance. Analysis with Arlequin software identified eight haplotypes from 
      three SNPs analyzed here. The distributions of IL-18 gene haplotypes were not 
      significantly different between patients and controls after Bonferroni 
      correction. DISCUSSION: This is the first report to investigate the association 
      between IL-18 polymorphism and lung cancer. Our results suggest that IL-18 
      polymorphism contributes to the lung cancer risk, particularly among SC patients. 
      Further studies with larger numbers of patients are required to determine the 
      possible association between IL-18 polymorphisms and different histological types 
      of lung cancer.
FAU - Farjadfar, Akbar
AU  - Farjadfar A
AD  - Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Mojtahedi, Zahra
AU  - Mojtahedi Z
FAU - Ghayumi, Mohammad Ali
AU  - Ghayumi MA
FAU - Erfani, Nasrollah
AU  - Erfani N
FAU - Haghshenas, Mohammad Reza
AU  - Haghshenas MR
FAU - Ghaderi, Abbas
AU  - Ghaderi A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Case-Control Studies
MH  - DNA, Neoplasm/analysis/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Haplotypes
MH  - Humans
MH  - Interleukin-18/*genetics/physiology
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Single Nucleotide
MH  - *Promoter Regions, Genetic
MH  - Small Cell Lung Carcinoma/*genetics
EDAT- 2009/07/31 09:00
MHDA- 2010/01/29 06:00
CRDT- 2009/07/31 09:00
PHST- 2009/07/31 09:00 [entrez]
PHST- 2009/07/31 09:00 [pubmed]
PHST- 2010/01/29 06:00 [medline]
AID - 913516397 [pii]
AID - 10.1080/02841860902878145 [doi]
PST - ppublish
SO  - Acta Oncol. 2009;48(7):971-6. doi: 10.1080/02841860902878145.